Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SLDBthis companySolid Biosciences Inc.	$6.98	-2.83×	2.74×	0×	-2.63×	-93.1%	0.0%	0.0%	0.0%	-96.8%	-89.1%	-31.9%	0.12×	0.22×	0×	6.14×	0.0%	2	4.16	2	C
CAPRCapricor Therapeutics, Inc.	$9.02	-12.77×	4.39×	0×	-10.7×	-20.2%	0.0%	0.0%	0.0%	-34.4%	-33.4%	-5.4%	0.06×	2.7×	-35.51×	9.01×	0.0%	2	0.16	2	C
DYNDyne Therapeutics, Inc.	$18.46	-5.64×	2.58×	0×	-3.74×	-61.0%	0.0%	0.0%	0.0%	-45.9%	-41.0%	-16.1%	0.02×	1.99×	-75.61×	22.25×	0.0%	2	3.6	2	C+
EWTXEdgewise Therapeutics, Inc.	$45.72	-15.23×	4.89×	0×	-15.09×	-98.7%	0.0%	0.0%	0.0%	-32.1%	-36.4%	-5.6%	0.01×	0.35×	0×	19.85×	0.0%	1	75.67	2	C
FDMT4D Molecular Therapeutics, Inc.	$12.59	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
MGTXMeiraGTx Holdings plc	$9.40	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
Peer median	—	-5.64×	2.58×	0×	-7.4×	-98.7%	0.0%	0.0%	0.0%	-32.1%	-36.4%	-7.8%	0.02×	0.35×	-8.69×	9.39×	0.0%	2	3.6	2	—